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Determination of meningioma brain tumour grades using Raman 
microspectroscopy imaging 
Camilo L. M. Morais,*a Taha Lilo,a,b Katherine M. Ashton,c Charles Davis,a Timothy P. Dawson,c 
Nihal Gurusingheb and Francis L. Martin*a 
Raman spectroscopy is a powerful technique used to analyse biological materials, where spectral markers such as proteins 
(1500-1700 cm-1), carbohydrates (470-1200 cm-1) and phosphate groups of DNA (980, 1080-1240 cm-1) can be detected in a 
complex biological medium. Herein, Raman microspectroscopy imaging was used to investigate 90 brain tissue samples in 
order to differentiate meningioma Grade I and Grade II samples, which are the commonest types of brain tumour.  Several 
classification algorithms using feature extraction and selection methods were tested, in which the best classification 
performances were achieved by principal component analysis-quadratic discriminant analysis (PCA-QDA) and successive 
projections algorithm-quadratic discriminant analysis (SPA-QDA), resulting in accuracies of 96.2%, sensitivities of 85.7% 
and specificities of 100% using both methods. A biochemical profiling in terms of spectral markers was investigated using 
the difference-between-mean (DBM) spectrum, PCA loadings, SPA-QDA selected wavenumbers, and the recovered 
imaging profiles after multivariate curve resolution alternating least squares (MCR-ALS), where the following 
wavenumbers were found to be associated with class differentiation: 850 cm-1 (amino acids or polysaccharides), 1130 cm-1 
(phospholipid structural changes), the region between 1230 – 1360 cm-1 (Amide III and CH2 deformation), 1450 cm-1 (CH2 
bending), and 1858 cm-1 (C=O stretching). These findings highlight the potential of Raman microspectroscopy imaging for 
determination of meningioma tumour grades. 
Introduction 
Raman spectroscopy provides sensitive spectrochemical 
signatures of materials based on their molecular polarisability 
changes.1 Raman is based on an inelastic scattering 
phenomenon that occurs in less than 1% of the absorbed 
photons by a molecule. This inelastic scattering is composed of 
Stokes and anti-Stokes scattering: the former occurs when the 
molecule emits a photon with less energy than the absorbed 
incoming radiation, and the latter happens when the molecule 
emits a photon with higher energy than the absorbed 
incoming radiation.2 At room temperature, the Stokes 
scattering is more frequent, thus most instruments filter the 
elastic and anti-Stokes scattering and record the Stokes 
scattering signal as the final Raman spectrum. 
Microspectroscopy Raman imaging allows one to obtain 
microscopically spatially distributed spectral data, where each 
position in the image is composed of a Raman spectrum in a specific 
wavenumber range. The hyperspectral image data are represented 
by three-dimensional (3D) arrays, where the spatial coordinates are 
present in the x- and y-axis while the spectral information is in the 
z-axis. A major advantage of Raman imaging is that it can be non-
destructive depending on the incident laser frequency, has 
minimum water interference, and has a relatively low cost in 
comparison with other analytical techniques. 
Raman imaging has been used in a wide range of applications, 
including pharmaceutical analysis,3 forensic investigations,4 food 
quality control,5 and to analyse biological materials.6 In the latter, 
cancer detection plays an important role, where Raman imaging has 
been successfully applied to investigate breast,7 cervical,8 lung,8 
skin,9 ovarian,10 and brain cancer.11 
Most of brain cancers are gliomas or meningioma tumours.12 
Gliomas are more aggressive types of tumours and have been 
widely investigated using Raman spectroscopy,12-15 while 
meningiomas remain to be intensively investigated using vibrational 
spectroscopy. Meningiomas represent 20% to 35% of all primary 
intracranial tumours.16 The majority of them occur in a 
supratentorial location; however, a few of them can arise in the 
posterior cranial fossa and, more rarely, as extracranial 
meningiomas.16 It usually manifests as single or sporadic lesions, 
causing symptoms such as sensory and motor deficits and gait 
disturbance; while multiple meningiomas are often associated with 
neurofibromatosis type II.17 Meningiomas can be divided into WHO 
Grade I, Grade II and Grade III. Grade I meningiomas are the 
commonest type of tumours, with slower growth and lower 
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likelihood of recurrence; Grade II meningiomas also have a slower 
growth but higher likelihood of recurrence; and Grade III 
meningiomas are a very rare type of tumour with fast growing rate 
and much higher likelihood of recurrence. Surgical outcomes and 
treatment are dependent on the meningioma grade and histological 
subtypes.17 
In this paper, Raman microspectroscopy imaging is applied to 
distinguish Grade I and Grade II meningiomas via the application of 
several chemometric approaches, including combination of feature 
extraction and selection methods with discriminant analysis 
techniques, and multivariate curve resolution alternating least 
squares (MCR-ALS) for profiling and differentiation of Grade I and 
Grade II tumour tissues. 
Materials and methods 
Samples 
Ninety brain tissue samples (66 meningiomas WHO Grade I, 24 
meningiomas WHO Grade II) were analysed by a Renishaw InVia 
Basis Raman spectrometer coupled to a confocal microscope 
(Renishaw plc, UK). All samples were sourced from the Brain 
Tumour North West (BTNW) biobank (NRES14/EE/1270). All 
experiments were performed in accordance with the STEMH 
(Science, Technology, Engineering, Medicine and Health) Guidelines 
at the University of Central Lancashire, and approved by the ethics 
committee at the University of Central Lancashire (STEMH 917). 
Informed consents were obtained from human participants of this 
study. Formalin-fixed paraffin-embedded (FFPE) tissue specimens 
(10-μm-thick) were placed onto aluminium-covered glass slides for 
spectroscopy measurement. Microspectroscopy imaging was 
performed with an acquisition area of approx. 100 x 50 μm (50× 
magnification, 785 nm laser, 50% laser power (150 mW), 0.1 s 
exposure time, 780–1858 cm-1 spectral range) using the 
StreamHRTM imaging technique (high-confocality mode) with a grid 
area of 42 x 28 pixels, resulting in 1176 spectra for each image (1 
cm-1 data spacing). The laser power was set relatively high to ensure 
a good signal-to-noise ratio. To minimize any potential 
photodamage to the sample, the laser exposure time was set to 
only 0.1 s. Moreover, no damage was visually observed in the 
samples after measurement. The imaging acquisition time was 
approx. 8 min for each sample. 
 
Computational analysis 
The Raman images were converted into suitable .txt files using the 
Renishaw WiRE software, and processed using MATLAB R2014b 
(MathWorks, Inc., USA) with lab-made routines. All the samples’ 
images were pre-processed by cosmic rays (spikes) removal, 
Savitzky-Golay smoothing (window of 15 points, 2nd order 
polynomial fitting), and asymmetric least squares baseline 
correction. The window size in the Savitzky-Golay smoothing was 
determined visually by testing different window sizes, where the 
smallest window size that removed random noise and kept the 
same spectral shape and intensity without smoothing-out relevant 
spectral peaks was chosen. MCR-ALS was applied to the image data 
using the HYPER-Tools toolbox in MATLAB.18  
 
First-order classification. Each pre-processed image with size 42 x 
28 x 1015 was averaged into a single spectrum (1 x 1015) as the 
classification was performed on a sample basis. Initially, an outlier 
detection test was performed by a Hotelling T2 versus Q residuals 
test.19 The remaining samples after outlier removal were split into 
training (60%), validation (20%) and test (20%) sets using the MLM 
sample selection algorithm.20,21 All data were mean-centred before 
further analysis. 
 For feature extraction and classification, principal component 
analysis combined with linear discriminant analysis (PCA-LDA), 
quadratic discriminant analysis (PCA-QDA) and support vector 
machines (PCA-SVM) were applied to the pre-processed data. PCA 
reduces the pre-processed spectral variables to a small number of 
principal components (PCs) responsible for the majority of the 
original data-explained variance. Each PC is orthogonal to each 
other and is generated in a decreasing order of explained variance, 
where the first PC explains most of the data variance, followed by 
the second PC, and so on. The PCs are composed of scores and 
loadings, the scores representing the variance on the sample 
direction, thus being used to identify similarities and dissimilarities 
between the samples; and, the loadings represent the variance on 
the wavenumber direction, being used to identify possible spectral 
markers associated with class differentiation.22 PCA decomposition 
takes the form:22 
 
𝐗 = 𝐓𝐏T + 𝐄              (1) 
 
where 𝐗 is a matrix containing the mean-centred pre-processed 
spectral data; 𝐓 is a matrix containing the PCA scores for a 
determined number of PCs; 𝐏 is a matrix containing the PCA 
loadings for a determined number of PCs; 𝐄 is a residual matrix; and 
the superscript T represents the matrix transpose operation. 
 In PCA-LDA, PCA-QDA and PCA-SVM, a PCA model is applied to 
the pre-processed data and then a LDA, QDA or SVM classifier is 
applied to the PCA scores, respectively. LDA and QDA are 
discriminant analysis methods based on a Mahalanobis distance 
calculation. LDA assumes classes having similar variance structures, 
therefore using a pooled covariance matrix to calculate the 
classification score for each class, while QDA assumes classes having 
different variance structures, therefore using the variance-
covariance matrix for each class individually when calculating the 
classification score.23,24 The LDA (𝐿𝑖𝑘) and QDA (𝑄𝑖𝑘) classification 
scores can be calculated in a non-Bayesian form by: 23,24 
 
𝐿𝑖𝑘 = (𝐱𝑖 − ?̅?𝑘)
T𝐂pooled
−1 (𝐱𝑖 − ?̅?𝑘)        (2) 
𝑄𝑖𝑘 = (𝐱𝑖 − ?̅?𝑘)
T𝐂𝑘
−1(𝐱𝑖 − ?̅?𝑘)         (3) 
 
where 𝐱𝑖  is a vector containing the input classification variables 
(e.g., PCA scores) for sample 𝑖; ?̅?𝑘  is the mean vector of input 
classification variables for class 𝑘; 𝐂pooled is the pooled covariance 
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matrix; and 𝐂𝑘  is the variance-covariance matrix of class 𝑘. 𝐂pooled 
and 𝐂𝒌 are calculated as follows:24 
 
𝐂pooled =
1
𝑛
∑ 𝑛𝑘𝐂𝑘
𝐾
𝑘=1            (4) 
𝐂𝑘 =
1
𝑛𝑘−1
∑ (𝐱𝑖 − ?̅?𝑘)(𝐱𝑖 − ?̅?𝑘)
T𝑛𝑘
𝑖=1         (5) 
 
in which 𝑛 is the total number of samples in the training set; 𝐾 is 
the total number of classes; and 𝑛𝑘 is the number of samples in 
class 𝑘.  
 SVM is a binary linear classifier with a non-linear step called the 
kernel transformation.25 A kernel function transforms the input 
data space into a feature space by a applying a mathematical 
transformation which is often non-linear. Then, a linear decision 
boundary is fit between the closest samples to the border of each 
class (called support vectors), where each class is defined. SVM 
classification is performed as follows:25,26 
 
𝑓(𝑥) = sign(∑ 𝛼𝑖𝑦𝑖𝛟(𝐱𝑖 , 𝐳𝑗) + 𝑏
𝑁𝑆𝑉
𝑖=1 )        (6) 
 
where 𝐱𝑖  and 𝐳𝑗  are vectors containing sample measurement 
vectors (e.g., PCA scores);  𝑁𝑆𝑉 is the number of support vectors; 𝜶𝒊 
is the Lagrange multiplier for sample 𝑖; 𝑦𝑖 is the class membership 
of sample 𝑖 (±1); 𝛟(𝐱𝑖 , 𝐳𝑗) is the kernel function; and 𝑏 is the bias 
parameter.  
 SVM was performed using a radial basis function (RBF) kernel, 
which is defined by:26 
 
𝛟(𝐱𝑖 , 𝐳𝑗) = 𝐞𝐱𝐩 (−𝛾‖𝐱𝑖 − 𝐳𝑗‖
2
)         (7) 
 
where 𝛾 is the kernel parameter that determines the RBF width. 
Cross-validation venetian blinds with 10 data splits was performed 
to optimise the bias and kernel parameter. 
 Some feature selection techniques were used to analyse the 
image spectral data. Successive projections algorithm (SPA)27 and 
genetic algorithm (GA)28 were used coupled with LDA, QDA and 
SVM. SPA is a forward feature selection method which operates by 
minimising the co-linearity of original pre-processed spectra; thus, 
selecting wavenumbers whose information content is minimally 
redundant.29 GA is an iterative algorithm inspired by Mendelian 
genetics, where the pre-processed spectral data is reduced to a set 
of selected wavenumbers based on an evolutionary process.28 For 
this, a set of variables is randomly chosen to go through 
combinations, cross-overs and mutations until the best set of 
variables reaches the minimum of a pre-defined cost function.2,28 
The optimum number of variables for SPA and GA is obtained by 
minimizing the average risk 𝐺 of misclassification in the validation 
set:29,30 
 
𝐺 =
1
𝑁𝑉
∑ 𝑔𝑛
𝑁𝑉
𝑛=1              (8) 
 
where 𝑁𝑉 is the number of samples in the validation set and 𝑔𝑛 is 
defined by: 
 
𝑔𝑛 =
𝑟2(x𝑛,𝑚𝐼(𝑛))
min𝐼(𝑚)≠𝐼(𝑛) 𝑟
2(x𝑛,𝑚𝐼(𝑚))
          (9) 
 
where 𝑟2(x𝑛, 𝑚𝐼(𝑛)) is the squared Mahalanobis distance between 
sample x𝑛 of class 𝐼(𝑛) and the centre of its true class (𝑚𝐼(𝑛)); and 
𝑟2(x𝑛, 𝑚𝐼(𝑚)) is the squared Mahalanobis distance between object 
x𝑛 and the centre of the closest incorrect class (𝑚𝐼(𝑚)). The GA 
routine was carried out using 100 generations containing 200 
chromosomes each. Cross-over and mutation probabilities were set 
to 60% and 1%, respectively. The algorithm was repeated three 
times, starting from different random initial populations, and the 
best solution in terms of fitness value was employed. 
MCR-ALS. Multivariate curve resolution alternating least squares 
(MCR-ALS) assumes a bilinear model that is the multi-wavelength 
extension of the Beer-Lambert’s law. It decomposes an 
experimental matrix 𝐃 into concentration and spectral profiles as 
follows:31 
 
𝐃 = 𝐂𝐒T + 𝐄              (10) 
 
where 𝐂 is a matrix containing the concentration profiles for a 
determined number of pure components in 𝐃; 𝐒 is a matrix 
containing the spectral profiles for the pure components in 𝐃; and 
𝐄 is a residual matrix. 
 MCR-ALS can remove noise and physical/chemical interferences 
from the spectral matrix 𝐃, and allow one to recover the pure 
concentration and spectral profiles of the components that make 
the spectral matrix 𝐃. MCR-ALS is very useful to handle image data 
since it allows the reconstruction of image maps based on the 
recovered concentration profiles, where one can identify spatial 
and chemical differences between the samples being imaged.32 
 
Model validation. The models were validated by calculating some 
quality parameters such as accuracy, sensitivity, specificity, and F-
score. Accuracy represents the total number of samples correctly 
classified considering true and false negatives; sensitivity represents 
the proportion of positives that are correctly classified; specificity 
represents the proportion of negatives that are correctly classified; 
and, F-score measures the model performance considering 
imbalanced data.33 The equations to calculate these parameters are 
depicted in Table 1. 
 
Table 1. Quality parameters for model validation. Where: TP stands 
for true positive, TN for true negative, FP for false positive, and FN 
for false negative. 
Parameter Equation 
Accuracy (%) 
(
TP + TN
TP + FP + TN + FN
) × 100 
Sensitivity (%) 
(
TP
TP + FN
) × 100 
Specificity (%) 
(
TN
TN + FP
) × 100 
F-score 2 × Sensitivity × Specificity
Sensitivity + Specificity
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 In addition, the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve was evaluated to assess model 
quality. AUC values between 0.7 and 0.8 are considered acceptable, 
between 0.8 and 0.9 are considered excellent, and above 0.9 are 
considered outstanding.34 
Results and discussion 
Ninety brain tissue samples (66 meningiomas Grade I, 24 
meningiomas Grade II) were analysed by Raman 
microspectroscopy imaging. The median microscopic and 
Raman image for meningiomas Grade I and Grade II are 
depicted in Figures 1a–1d (the colour figures represent the 
mean response (average Raman intensity between 780–1858 
cm-1) of the median image for each group). Notably, each 
image presents different visual features due to the different 
distributions of chemicals on the sample surface, but their 
spectrochemical profile are very similar as shown in Figure 1e 
and 1f, indicating that chemical differences between 
meningiomas Grade I and Grade II are not visually clear.  
 The pre-processed spectra from the images acquired in the 
spectral range between 780–1858 cm-1 (Figure 1f) were used 
for further analysis. This spectral region includes the Raman 
fingerprint region, hence, encompassing spectrochemical 
signals of the main biomolecules present in the tissue 
samples.1 The assignment of the main peaks of the pre-
processed Raman spectrum is depicted in Figure 1f. These 
include C-C stretching [ν(C-C)1] in amino acids or 
polysaccharides at 850 cm-1, C-C stretching [ν(C-C)2] in proteins 
at 890 cm-1, C-C stretching [ν(C-C)3] in amino acids at 930 cm-1, 
C-C stretching [ν(C-C)4] in phenylalanine at 1003 cm-1, 
phospholipid structural changes at 1130 cm-1, Amide III peak at 
1265 cm-1, CH2 bending [δ(CH2)1] in lipids at 1296 cm-1, 
CH3/CH2 deformation modes in DNA/RNA at 1336 cm-1, CH2 
bending [δ(CH2)2] in malignant tissues at 1450 cm-1, NH2 
bending [δ(NH2)] in cytosine at 1610 cm-1, and Amide I 
absorption at 1665 cm-1.35 Some of these peaks are 
discriminant features between the samples and some of them 
are common amongst the tumour types. The identification of 
relevant distinguishing spectral features between Grade I and 
Grade II samples are achieved by chemometric techniques. 
Initially, outlier detection was performed by a Hotelling T2 
versus Q residuals test, where 4 samples (2 meningiomas 
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Figure 1. Median Raman miscrospectroscopy images. (a) Microscopic image of Grade I meningioma tissue; (b) microscopic image of Grade II  meningioma tissue; (c) median raw 
image for meningioma Grade I samples; (d) median raw image for meningioma Grade II samples; (e) median raw spectra for meningiomas Grade I and Grade II; (f) median pre-
processed spectra (Savitzky-Golay smoothing and asymmetric least squares baseline correction) for meningiomas with a tentative assignment of the main Raman peaks. Grade I 
and Grade II. Colour bar: Raman intensity. ν: stretching vibration, δ: bending.  
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Grade I, 2 meningiomas Grade II) were removed (see 
Electronic Supplementary Information (ESI) Figure S1). First-
order algorithms were used to analyse the pre-processed 
spectral data after outlier removal. 
 Feature extraction and classification by means of PCA-LDA, 
PCA-QDA and PCA-SVM; and feature selection and 
classification by means of SPA-LDA, SPA-QDA, SPA-SVM, GA-
LDA, GA-QDA and GA-SVM, were applied to distinguish 
meningiomas Grades I and II on sample basis. Amongst the 
PCA-based algorithms (using 8 PCs, 98.94% explained variance, 
see ESI Figure S2), the best performance was obtained with 
PCA-QDA (96.2% accuracy, 85.7% sensitivity, 100% specificity, 
and F-score = 92.3%). Also, SPA-QDA was the best algorithm 
amongst SPA-based methods, with the same performance of 
PCA-QDA. GA-based methods showed overall poorer 
performance, where the best algorithm (GA-QDA) achieved 
73.1% accuracy but 0% sensitivity, indicating that GA-based 
models are most likely overfitted. More details about the 
predictive performance of each of these algorithms are 
provided in Table 2. 
 The ROC curve for PCA-QDA and SPA-QDA models are 
shown in Figure 2, where the AUC value was found at 0.929 
indicating an outstanding classification performance for both 
algorithms. 
 
Table 2. Quality parameter for distinguishing Grade I and 
Grade II meningiomas in the test set. 
Algorithm Accuracy Sensitivity Specificity F-score 
PCA-LDA 46.2% 85.7% 31.6% 46.2% 
PCA-QDA 96.2% 85.7% 100% 92.3% 
PCA-SVM 61.6% 28.6% 73.7% 41.2% 
SPA-LDA 57.7% 100% 42.1% 49.3% 
SPA-QDA 96.2% 85.7% 100% 92.3% 
SPA-SVM 34.6% 71.4% 21.1% 32.5% 
GA-LDA 61.5% 57.1% 63.2% 60.0% 
GA-QDA 73.1% 0% 100% 0% 
GA-SVM 42.3% 42.9% 42.1% 42.5% 
 
 QDA-based algorithms exhibit superior performance in 
comparison with LDA- and SVM-based methods. Usually, for 
complex biological data, QDA outperforms LDA since QDA-
based algorithms model each class variance individually, while 
LDA assumes classes having similar variance structures.24 This 
occurs because the performance of QDA ultimately depends 
on the variance structure of the data. QDA is expected to work 
better than LDA for most biological applications, since quite 
commonly biological samples are composed of complex 
chemical matrices with different variances structures for each 
class. For example, diseases’ samples can have a smaller 
variance distribution than healthy control samples, since the 
latter can be composed of individuals with different life habits, 
while patients with a same specific disease usually have a 
similar life-style. The same can occur with different tumour 
grades, where one class can assume a different variance 
distribution in comparison with the other. The only situation 
where QDA underperforms LDA is when the number of 
samples in the dataset is small,36 since the variance of each 
group might not be totally covered by QDA hence increasing 
the degree of extrapolation needed and commonly leading the 
model to overfitting. 
SVM-based models seem to be highly overfitted, since the 
training performance for these algorithms are excellent (see 
ESI Table S1), with near 100% correct classification rates; 
however, test performance is highly affected as demonstrated 
in Table 2. SVM classification performance would probably 
improve by adding more samples to the training set, thus 
creating a most representative training model. Nevertheless, 
PCA-QDA and SPA-QDA performance are both excellent in the 
test set, indicating that these algorithms are robust to provide 
a satisfactory prediction towards external samples. 
Figure 2. Receiver operating characteristic (ROC) curve for PCA-QDA and SPA-QDA. 
AUC: area under the curve.
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 The difference-between-mean (DBM) spectrum, PCA 
loadings on PC1 (56.64% explained variance), and SPA-QDA 
selected variables are shown in Figure 3. The PCA loadings 
indicate higher coefficients at ~850 cm-1, ~1003 cm-1, ~1130 
cm-1, ~1337 cm-1, ~1450 cm-1,  ~1665 cm-1, and ~1858 cm-1; 
and the SPA-QDA selected variables are: ~850 cm-1, ~1130 cm-
1, ~1245 cm-1, ~1337 cm-1, ~1450 cm-1, and ~1858 cm-1. Only 
the variable at 1245 cm-1 selected by SPA-QDA does not have a 
high PCA loadings, while the other variables selected by SPA-
QDA are very close or are a perfect match with the ones 
observed in PCA-QDA. The list of PCA and SPA-QDA selected 
variables and tentative assignment according to Movasaghi et 
al.35 are shown in Table 3. The Raman shift at 1858 cm-1 is 
unknown based on this reference, but this wavenumber has 
been associated to C=O stretching in other literature.37 The 
peak at around 850 cm-1 has been previously detected in 
meningioma samples as belonging to tyrosine,38 an α-amino 
acid that constitute important structures in proteins 
responsible for signal transduction processes;39 and the peaks 
at 1003 cm-1 (phenylalanine) and 1450 cm-1 (CH2 bending in 
DNA) have also been reported as biomarkers of meningioma 
tumours.38,40 Phospholipids (1130 cm-1), Amide III (1245 cm-1) 
and Amide I (1665 cm-1) have been reported for brain tumours 
in general.12,40  
 
 
 
 
 
Table 3. Tentative assignment of PCA and SPA-QDA selected 
variables to distinguish meningiomas Grade I and Grade II. 
DBM: difference-between-mean spectrum, where ↑ 
represents higher intensity in meningioma Grade I samples, 
and ↓ represents higher intensity in meningioma Grade II 
samples. 
Peak Algorithm Assignment DBM 
850 cm-1 PCA/SPA-QDA Amino acids or 
polysaccharides 
↑ 
1003 cm-1 PCA C-C in phenylalanine ↑ 
1130 cm-1 PCA/SPA-QDA Phospholipid 
structural changes 
↓ 
1245 cm-1 SPA-QDA Amide III ↑ 
1337 cm-1 PCA/SPA-QDA Amide III and CH2 
wagging vibrations 
↑ 
1450 cm-1 PCA/SPA-QDA CH2 bending ↑ 
1665 cm-1 PCA Amide I ↑ 
1858 cm-1 PCA/SPA-QDA C=O stretching ↑ 
  
MCR-ALS was employed to resolve the median Grade I and 
Grade II meningioma images in order to identify 
spectrochemical changes associated with tumour 
aggressiveness. MCR-ALS was performed with 4 components 
selected by singular value decomposition (99.99% explained 
variance, 0.21 lack of fit, non-negativity in concentration 
mode). The recovered concentration and spectral profiles of 
the 4 components are depicted in the ESI Figure S3. The 1st 
component of MCR-ALS was found to be associated with 
Grade II appearance (Figure 4a), once it is clearly present in 
a.
b.
c. ν(C-C)
amino acids/
polysaccharides
Phospholipid 
structural 
changes
Amide III
Amide III / 
CH2 wagging
δ(CH2)
v(C=O)
Figure 3. PCA loadings and SPA-QDA selected variables. (a) Difference-between-mean (DBM) spectrum (+ values: higher intensity in meningioma Grade I samples; - values: higher 
intensity in meningioma Grade II samples); (b) PCA loadings on PC1; (c) average training set spectrum and SPA-QDA selected variables (red circles) with their tentative assignment. 
ν: stretching vibration, δ: bending.  
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the Grade II tissue sample. The spectral profile of the 1st 
component (Sopt 1) indicates distinguishing features at the 
region between 1230 cm-1 and 1360 cm-1 in comparison with 
the spectral profiles for other components (see ESI Figure S3), 
where three peaks (1265 cm-1, 1296 cm-1 and 1336 cm-1) are 
presents. These peaks are associated with Amide III, CH2 
deformation in lipids, and CH2/CH3 twisting in polynucleotide 
chains, respectively.35 This region encompasses the 
wavenumber at 1337 cm-1 (amide III and CH2 wagging 
vibrations) in Table 3. Similarly to Figure 1f, the peaks at 850 
cm-1 [ν(C-C)1, amino acids or polysaccharides], 890 cm-1 [ν(C-
C)2, proteins], 930 cm-1 [ν(C-C)3, amino acids], 1003 cm-1 [ν(C-
C)4, phenylalanine], 1130 cm-1 (phospholipids), 1265 cm-1 
(Amide III),  1296 cm-1 [δ(CH2)1, lipids], 1336 cm-1 [δ(CH3/CH2), 
DNA/RNA], 1450 cm-1 [δ(CH2)2, malignant tissue], and 1665 cm-
1 (Amide I) are also present. In addition, other peaks at 1060 
cm-1 [ν(PO2-), DNA/RNA], 1100 cm-1 [ν(C-C)5, lipids], and a small 
arm at 1459 cm-1 [δ(CH2)3, deoxyribose]35 are observed as 
distinguishing features in the MCR-ALS Sopt 1 profile. 
 Bury et al.15 have recently used Raman spectroscopy to 
discriminate meningioma Grade I brain tissue among different 
brain pathologies (low-grade glioma, high-grade glioma, 
metastasis, lymphoma, and no-tumour) with 94.8% accuracy, 
63.9% sensitivity and 97.1% specificity using PCA-LDA with 
smear-based samples; and, meningioma Grade I brain tissue 
among low-grade glioma, high-grade glioma, metastasis and 
lymphoma with 90.8% accuracy, 91.7% sensitivity and 90.8% 
specificity using PCA-LDA with FFPE samples. Mehta et al.38 
have recently used Raman spectroscopy to discriminate 
healthy controls and meningioma patients based on serum 
using PCA-LDA. Seventy patients (35 controls, 35 
meningiomas) were analysed, resulting in 70% accuracy to 
distinguish meningiomas versus controls in an independent 
test set; 72% accuracy to distinguish meningiomas Grade I 
versus controls; and 80% accuracy to distinguish meningiomas 
Grade II versus controls. The results reported herein (96.2% 
accuracy, 85.7% sensitivity, 100% specificity) are very 
promising to distinguish meningioma tissue grades, which is 
critical to delineate patient treatment; and also evidences the 
potential of Raman spectroscopy to investigate brain tumour 
tissues. 
 
Conclusion 
Ninety meningioma brain tissue samples (66 meningiomas 
Grade I, 24 meningiomas Grade II) were investigated using 
Raman microscpectroscopy imaging. Several chemometric 
algorithms were applied to distinguish the samples according 
to the tumour grade, where PCA-QDA and SPA-QDA were 
found to have to best classification performance at 96.2% 
accuracy, 85.7% sensitivity and 100% specificity (AUC = 0.929). 
Spectral bio-markers at 850 cm-1, 1130 cm-1, 1337 cm-1, 1450 
cm-1 and 1858 cm-1 were found in common using both PCA-
QDA and SPA-QDA, and a further analysis using MCR-ALS 
indicated distinguishing features at the region between 1230 – 
1360 cm-1 associated with increases in the WHO meningioma 
tumour grade. The classification results found by PCA-QDA and 
SPA-QDA are very promising, and show the potential of Raman 
microspectroscopy to distinguish meningioma tissue grades, 
thus aiding clinicians to delineate patient treatment. 
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